Blood protein predictors of brain amyloid for enrichment in clinical trials?

BACKGROUND: Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood-based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large-scale prevention t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashton, Nicholas J., Kiddle, Steven J., Graf, John, Ward, Malcolm, Baird, Alison L., Hye, Abdul, Westwood, Sarah, Wong, Karyuan Vivian, Dobson, Richard J., Rabinovici, Gil D., Miller, Bruce L., Rosen, Howard J., Torres, Andrew, Zhang, Zhanpan, Thurfjell, Lennart, Covin, Antonia, Hehir, Cristina Tan, Baker, David, Bazenet, Chantal, Lovestone, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Blood-Based Biomarker
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876903/
https://www.ncbi.nlm.nih.gov/pubmed/27239491
http://dx.doi.org/10.1016/j.dadm.2014.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876903/
https://www.ncbi.nlm.nih.gov/pubmed/27239491
http://dx.doi.org/10.1016/j.dadm.2014.11.005

Ejemplares similares